Polybrominated flame retardants by Boer, J., de & Sakai, S.
POLYBROMINATED FLAME RETARDANTS 
Jacob de Boer' and Shin-ichi Sakai2 
'Netherlands Institute for Fisheries Research (RIVO), Umuiden, The Netherlands 
2National Institute for Environmental Studies, Ibaraki, Japan 
Since 1998 brominated flame retardants (BFRs) have drawn a lot of attention at the Dioxin 
conferences. Although they have been reported to be present in the environment in the early 1980's, the 
discovery of their presence in human milk and in whales, both presented at Dioxin 1998 in Stockholm, 
initiated much activity in environmental laboratories. Many interesting papers have been presented 
during the Dioxin conferences in Venice, Monterey and Gyongju. Many laboratories have developed 
analytical methods, in particular for polybrominated diphenylethers (PBDEs). PBDEs have been 
detected in various biota and sediments from the aquatic environment, air, human milk, blood and 
adipose tissue, bird eggs, various foodstuffs and other matrices. 
A substantial number of papers of the total of 24 papers presented at Dioxin 2002 gives new 
information on human exposure to BFRs. Van Bavel et al. analysed 220 blood samples from Sweden. 
Background levels varied between 1 and 6 ng/g for the sum of PBDEs, on a lipid weight basis (lw.), but 
in 5 % of the samples SPBDE concentrations of over 30 ng/g lw. were found, possibly indicating an 
unknown source of PBDEs. Thuresson et al. found decaBDE concentrations of up to 300 ng/g lw. in 
blood of rubber workers, producing and handling rubber containing decaBDE as a flame retardant. 
Indications of a relatively short half-live of decaBDE in human blood (ca. 15 days) were found. 
TBBP-A concentrations in blood from workers in a printed circuit board recycling plant were below 
the limits of quantification, probably due to a limited exposure and short half-live of TBBP-A in 
humans. Choi et al. report a 44-fold increase of SPBDE concentrations in human adipose tissue from 
Japan, over the period 1970-2000, resulting in SPBDE concentrations of 466-2750 pg/g lw. The 
presence of brominated dioxins and furans in human adipose tissue is reported for the first time. No 
significant trend was found from 1970 to 2000, 5.1-4.0 pg/g respectively for SPBDD/Fs. The PBDE 
data are confirmed by Hori et al. who report an increase of PBDE concentrations in stored human milk 
samples of ND to 1.6 ng/g lw, from 1973 to 1988 and levels between 1 and 2 ng/g since then. The 
presence of PBDEs in human adipose tissue from the Czech Republic is also reported (Crhova et al.) 
S.-J. Lee et al. report human blood levels of PBDEs in Korea. Ryan et al. report 10-fold higher SPBDE 
concentrations in Canadian human milk, compared to those in Swedish human milk, earlier reported by 
Meironyté ad Nore'n. Also, a 15-fold increase is reported for SPBDE levels in human milk from 
Vancouver. Time trends of PBDEs in human milk from Uppsala, Sweden (Darnerud et al.) confirm the 
earlier work of Meironyté and Norén. Lind et al. give an overview of the intake of PBDEs and HBCD. 
Interestingly, the estimated HBCD intake, although based on somewhat preliminary data, is 3-fold 
higher than that of SPBDEs. The most important food group for PBDEs intake is fish, which 
constitutes two thirds of the total intake. Petreas et al. report high PBDE concentrations (up to 500 mg./ 
g lw. for BDE47) in human serum from California, as well as relatively high PBDE concentrations in 
human adipose tissue. 
The quantity of new information on human exposure to BFRs, in some cases resulting in relatively 
high PBDE concentrations in human blood, milk, and adipose tissue, further emphasizes the need for 
more toxicological information on BFRs. Such information is badly needed for a better understanding 
of the relevance of the concentrations reported and their possible effects. Unfortunately, almost no new 
46 ORGANOHALOGEN COMPOUNDS Summary and Supplement 
toxicity data have been forwarded for presentation at this session. Further toxicological studies should 
therefore be strongly encouraged. Huwe et al. present the results of a mass balance feeding study of a 
commercial octabromodiphenyl ether mixture in rats. The bioaccumulation decreased with higher 
bromination. Stapleton et al. suggest a possible degradation of BDE183 down to BDE154 in a feeding 
study of common carp, either by biotransformation or by debromination prior to the uptake by the carp. 
Knoth et al. report on a different source of PBDEs: house dust. Relatively high concentrations of in 
particular BDE209 (mean 1394 ng/g, maximum 19,100 ng/g) were found. Leakage of BFRs from 
consumer products is suggested, but is not confirmed. Exposure paths of PBDEs are not clear yet. It is 
unclear if for PBDEs the same exposure routes are valid as for other persistent organic contaminants: 
are the food intake processes predominant or is there any possibility of another process through 
inhalation or through dermal contact? These questions would require more attention in the near future. 
In addition to papers on human exposure, a number of other papers focus on BFR levels in 
environmental samples. Sakai et al. report on PBDE concentrations in sediment cores from Osaka Bay, 
Japan. The PBDE peak was found in the upper levels of the cores at a point where PCB concentrations 
had already substantially decreased. This trend in the sediment cores was related to the industrial 
production of PBDEs. Relatively low SPBDE concentrations (0.4-18 ng/g dry weight) were found in 
Portuguese river sediments (Lacorte el at.). Higher PBDEs levels were found in sediment from major 
Minnesota rivers (USA) (Oliaei et al.). In contrast, SPBDE concentrations in South Korean sediments 
are low (1.7-5.9 ng/g dry weight), but TOC data are needed for a correct interpretation. Ohta et al. 
detected PBDDs/DFs and PXDDs/DFs in marine sediments. TBDD, PeBDD and TXDD of 2,3,7,8 
substitution congeners in particular were relatively high in concentration. They suggested that PXDDs/ 
DFs TEQ values could exceed the TEQ of PCDDs/DFs. 
Lepom et al. report the presence of BDE209 in bream from the river Elbe (Germany), in 
concentrations up to 37 ng/g Iw. This is the first report on the presence of decaBDE in European 
freshwater fish. DecaBDE was not found in eel from the same river. 
R.G. Lee et al. report atmospheric concentrations of PBDE in samples from the Irish west coast and 
the UK. The Irish samples show 3-fold lower PBDE concentrations than those from the UK. 
The results of the second international interlaboratory study on BFRs are reported by de Boer et al. 
Results were obtained of 36 laboratories from 13 different countries. Eighteen laboratories had 
participated in the first round. This shows the increasing interest in this field over the last three years. 
Progress was made for the comparability of BDE99 and other PBDE data, but the analysis of BDE209 
in biota and sediments is still not under control by the majority of the laboratories. A coefficient of 
variation (CV) of 65 % (n = 13) was obtained for the analysis of a sediment sample. The CVs for the 
biota analyses were >100 %. Obviously, laboratories should be encouraged to improve their BDE209 
analysis. Relatively few sets of results were returned for HBCD and TBBP-A, which shows that many 
laboratories are still installing methods for these BFRs. 
Hori et al. and Eljarrat et al report two new methods for PBDE analysis. 
A paper of Muir and Alaee on a cost/benefit analysis of BFRs concludes that a continued use of 
BFRs would lead to very large human heath and economic costs and consequences. 
The data presented show that PBDEs are global contaminants that have a tendency to increase in 
concentration in the environment and human samples in some parts of the world, in particular in North 
America. The exposure data call for further toxicological studies to assess their relevance and possible 
effects. The analytical comparability is acceptable for a number of PBDE congeners but not for 
BDE209. It should, therefore, be kept in mind that some of the BDE209 data reported do have the 
quality that is required for publication. Laboratories are encouraged to improve their methods for this 
BDE, and further develop methods for other BFRs such as HBCD and TBBP-A. 
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BIOANALYSIS 
Detection and quantitation of polychlorinated dibenzo-p-dioxins (PCDDs), biphenyls (PCBs) and 
dibenzofurans (PCDFs) and related chemicals (polycyclic aromatic hydrocarbons, chlorinated 
pesticides, brominated flame retardants, and other POPs) has commonly employed instrumental 
analysis procedures (i.e. high resolution gas chromatography and mass spectrometry (HRGC/MS)) that 
require highly sophisticated equipment and training and are also very costly and time-consuming. Over 
the past several years, numerous bioanalytical and bioassay methods have been developed that can 
provide an inexpensive and rapid alternatives in which to detect and/or estimate the relative biological/ 
toxic potency of individual POPs or complex mixtures containing POPs. Bioanalytical methods are 
generally based on the ability of a chemical(s) to be specifically recognized and bound by antibodies 
(immunoassays) or their ability to induce a specific biological response in vitro or in cells in culture 
(bioassays). Immunoassay-based bioanalytical approaches utilize reagents (antibodies) which are 
generated against a specific chemical structure and as such, they tend to be relatively specific for a 
given chemical or closely related chemicals. Bioassay approaches for chemical detection are generally 
less specific than immunoassay approaches and they are based on the ability of a chemical or chemical 
class to affect a specific biological response or pathway. Accordingly, taking advantage of the 
molecular mechanism of action of PCDDs and related chemicals, several Ah receptor (AhR) based 
bioassay systems have been developed and optimized for the detection and quantitation of PCDDs, 
PCDFs, PCBs and related POPs. Numerous studies have demonstrated that bioanalytical methods can 
be used as valid approaches for the rapid and inexpensive detection and relative quantitation of PCDD 
and related chemicals and even the identification of novel POPs. However, even given the advantages 
of bioanalytical approaches, these methods have not gained widespread use and this likely results from 
the lack of regulatory acceptance of these new methods. Although these bioanalytical methods have 
been in place for years, extensive validation studies are now being conducted and as such, these 
methods are only now being examined in detail and considered as screening methods. The availability 
of fully-validated and accepted alternative bioanalytical methods for POPs detection and analysis will 
greatly facilitate many large scale screening studies where the equipment and/or funding is limited (as 
it usually is). The results and process necessary to gain regulatory acceptance of these alternative 
bioanalytical methods are critical issues that need to be resolved. 
This session on Bioanalysis includes nine platform presentations that address the development, 
application, validation and limitations of selected bioanalytical approaches. The first talk by Dr. Akira 
Okuyama describes the development of an enzyme-linked immunosorbent assay (ELISA) for 
quantitation of coplanar PCBs using a monoclonal antibody generated against PCB 118. These studies 
are unique in that the majority of available ELISA assays are for the detection of PCDDs. The assay 
was sensitive, with a minimal detection limit for their ELISA assay was 34.6 ng/ml (1.7 ng/well) for 
PCB118. Although this antibody shows minimal cross reactivity with numerous other coplanar PCBs 
(i.e. 3,3',4,4',5-TCB) and essentially no cross-reactivity with PAHs and related compounds, given the 
ubiquitous nature of PCB 118, the ELISA can be used as a sensitive tool for prescreening of samples for 
coplanar PCBs. The next two talks describe the development and application of new technologies for 
detection of PCDDs and PCDFs. Application of the AH-immunoassay (AH-I) for dioxin screening is 
presented by Dr. Yasuo Kobayashi. This assay systems measures chemical-dependent activation of the 
DNA binding activity of the AhR complex and measurement of the amount of complex using an 
antibody-based colorimetric assay. Using this system, the authors report that this bioassay has a 
minimal detection limit of 1 pg TEQ/g sample and a dynamic range of measurment of~20,000 pg 
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TEQs/g. Significant cross-reactivity with other HAHs and PAHs exists and the degree of cross 
reactivity correlates with WHO-TEFs. Analysis of ash and soil samples revealed a good correlation 
between TEQs estimated by the AH-I and HRGC/MS, although a 10-13 fold higher estimate was 
obtained with the AH-I system. Several explanations are put forward to account for this elevated 
activity. The second new bioassay is the real-time PCR assay (AhRC PCR) and is presented by Dr. 
Randy Allen. This bioassay assesses chemical-dependent activation of the DNA binding activity of the 
AhR complex by a given sample and estimates the amount of AhR ligand by quantitation of the amount 
of DNA that is captured by the activated AhR using the polymerase chain reaction and fluorescent 
probes. Increasing amount of AhR ligand in a given sample (i.e. PCDDs, PCDfs and PCBs) will result 
in an increase in the amount of DNA captured, with a resulting increase in fluorescence. The authors 
report that the minimal detection limit for TCDD was than 0.31 pg per well. 
The next two talks describe application of cell-based gene expression bioassay systems for the 
identification of bioactive chemicals present in complex mixtures. Dr. Helena Olsman describes the 
application of the ethyoxyresorufin O-deetylase (EROD) cell bioassay for bioassay-directed chemical 
fractionation procedures to identify chemicals present in anaerobically digested organic matter that 
exhibit dioxin-like activity. The authors demonstrated that di- and polyaromatic fractions of both 
mesophilic and thermophilic treatments induced EROD activity. Since further fractionation resulted in 
higher overall inducibility, suggesting the presence of inhibitors in the complex mixtures, real world 
samples may actually contain much higher levels of TEQs than estimated from the original extracts. Dr. 
Corine Houtman describes the application of recombinant AhR- and estrogen receptor-response 
luciferase cell lines for use in toxicity identification evaluation (i.e. bioassay-directed chemical 
fractionation procedures) for detection of endocrine disrupting chemicals in sediment samples. Initial 
experiments established the methodology and its subsequent application to sediment samples allowed 
partial fractionation of polar and nonpolar chemicals with estrogenic activity. These studies suggest 
that these systems can be used to identify unknown bioactive chemicals in complex mixtures. 
Although numerous laboratories have used the recombinant AhR -response luciferase cell lines for 
detection and relative quantitation of PCDDs and related chemicals and have shown that the results of 
these bioassay analysis are comparable to that of HRGC/MS, these results have not been considered by 
many as truly quantitative TEQ results. Dr. Use Van Overmeire discusses the required performance 
characteristics necessary to validate the recombinant luciferase cell bioassay system as a quantitative 
screening method. They describe an approach to determine the confirmation range of bioassay data 
necessary to reduce the number of true negative or true positive samples that must sent for confirmation 
by HRGC/MS. In addition, they describe a calculation model for the detection limit of a procedures. 
Although recovery determinations are required for quantitative instrumental analysis methods, these 
established procedures can not be used for bioassay screening methods. Dr. David Brown describes 
recovery determination approaches that have application for cell bioassay analysis. These corrections 
methods need to be included in bioassay analysis in order to avoid under reporting of the TEQ 
contamination of samples. The authors report that the use of biologically inactive congeners as internal 
spikes for their cell bioassay studies allow for accurate estimation of recovery efficiency. 
The focus of the final two talks is related to the use of bioassay and bioanalytical approaches for 
bio-monitoring and screening of samples for further analysis. Dr. Hidetaka Takigami describes 
validation studies for biomonitoring of waste PCB in contaminated samples of mineral insulating oil 
and capacitor oil. Using a combination of the dioxin-response luciferase cell bioassay system and a 
PCB immunoassay with sample cleanup procedures, the authors not only demonstrate a good 
correlation between results obtained using each bioassay method, but their results support the use of 
these methods for biomonitoring purposes. In the final presentation, Dr. Kim Hooper and coworkers 
describes the results of studies designed to use the luciferase cell bioassay system to both screen 
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mothers in southern Kazakhstan to identify those containing high levels of TCDD and to map the time 
course of TCDD elimination via breast milk. Their results not only suggests that the luciferase cell 
bioassay is useful both as a screening assay to select individuals with high TCDD TEQs for 
epidemiology studies, but that the bioassay can also be used as a quantitative measure of TEQs in 
breast milk samples. 
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